Bacterial vaginosis is an imbalance of "good" and "bad" bacteria in the vagina, with there being more bad bacteria. Causes of an imbalance of bacteria can be caused by multiple sex partners and douching. Symptoms include odor, discharge, burning, and itching. Treatments for bacterial vaginosis include the use of probiotics and medication. Common drug classes include lincosamide antibiotics and nitroimidazole antibiotics.
One driver in the market is unmet demand in BV treatment market. Unmet demand in the treatment of BV has created great opportunity for the market players. There is huge unmet need in the treatment of BV, especially the recurrent form of the disease. BV is the most common vaginal infection in the women of child bearing age group. Despite being highly prevalent in nature, little has been done in the field. When left untreated, it may lead to severe infections, especially in the case of pregnant women such as preterm births. rising awareness about women's health as one of the primary growth factors for the bacterial vaginosis drugs market. Owing to recent advancements in healthcare and the initiatives taken by the government and non-government organizations to increase the awareness about health of women, the demand for pharmaceuticals related to disorders in women will witness a significant increase in the coming years. Additionally, support from government is also a key driver.
In 2019, the market size of Bacterial Vaginosis Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Bacterial Vaginosis Drugs.

This report studies the global market size of Bacterial Vaginosis Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Bacterial Vaginosis Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Bayer
Pfizer
Sanofi
Starpharma Holdings
...

Market Segment by Product Type
Oral
Topical

Market Segment by Application
Pelvic Inflammatory Disease
Preterm Delivery of Infants
Urinary Tract Infection
Sexually Transmitted Diseases (STD)

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Bacterial Vaginosis Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Bacterial Vaginosis Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Bacterial Vaginosis Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025